You are here

BeiGene

5 New Drug Approvals the FDA Gave Top Priority

5 New Drug Approvals the FDA Gave Top Priority

Motley Fool

Global Blood Therapeutics

Vertex Pharmaceuticals

Flag link:

FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates

FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates

RAPS.org

Vertex Pharmaceuticals

Global Blood Therapeutics

Flag link:

China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

Yahoo/Reuters

mantle cell lymphoma

Flag link:

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1

Endpoints

Flag link:

Amgen pays $2.7bn to harness BeiGene’s China marketing muscle

Amgen pays $2.7bn to harness BeiGene’s China marketing muscle

Pharmaforum

Flag link:

BeiGene's first U.S. NDA tests global development strategy

BeiGene's first U.S. NDA tests global development strategy

BioCentury

drug development

Flag link:

The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)

The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)

Yahoo/Motley Fool

Bristol-Myers Squibb

Flag link:

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

Endpoints

Bristol-Myers Squibb

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

Yahoo/Benzinga

Akero Therapeutics

Dermavant Sciences

Prevail Therapeutics

Stoke Therapeutics

Flag link:

Upcoming events – Crucial data on zanubrutinib and filgotinib approach

Upcoming events – Crucial data on zanubrutinib and filgotinib approach

EP Vantage

Waldenström’s macroglobulinemia

Sjögren’s syndrome

Flag link:

Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx

Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx

Endpoints

Flag link:

Smaller groups await Bristol-Myers Squelgene fallout

Smaller groups await Bristol-Myers Squelgene fallout

EP Vantage

Bristol-Myers Squibb

Vividion Therapeutics

Skyhawk Therapeutics

Dragonfly Therapeutics

Agios Pharmaceuticals

Jounce Therapeutics

Flag link:

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

Endpoints

Flag link:

BMS deal weighs on Celgene partners

BMS deal weighs on Celgene partners

BioCentury

Bristol-Myers Squibb

Flag link:

BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics

BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics

Fierce Biotech

bispecific antibodies

Flag link:

BeiGene Announces Acceptance of its NDA in China for Zanubrutinib in Certain Types of Leukemia and Lymphoma

Flag link:

BeiGene Presents Data on it PARP Inhibitor in Combination With Temozolomide in Solid Tumors

BeiGene Presents Data on it PARP Inhibitor in Combination With Temozolomide in Solid Tumors

CP Wire

Flag link:

BeiGene Presents Data on it PARP Inhibitor in Combination With Temozolomide in Solid Tumors

Flag link:

BeiGene Presents Encouraging Results in Ph I Trial of Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors

Flag link:

Pages